Cellectar Biosciences (CLRB) Stock Price, News & Analysis

Company Overview

Cellectar Biosciences, Inc. (NASDAQ: CLRB) is a clinical-stage biopharmaceutical company focused on developing targeted radiopharmaceuticals and drug-delivery technologies for the treatment of cancer. The company’s approach is based on phospholipid ether (PLE) compounds, which are designed to selectively accumulate in cancer cells and other tumor-associated tissues.

Cellectar’s lead product candidate is iopofosine I 131, also known as CLR 131, a targeted radiotherapeutic being developed for hematologic malignancies, including certain forms of B-cell lymphoma and multiple myeloma. The company has also investigated its PLE platform for applications involving solid tumors and non-radioactive therapeutic agents.

Founded in the United States, Cellectar is headquartered in Florham Park, New Jersey. Its activities are primarily centered on research, clinical development and regulatory advancement of its oncology pipeline. The company’s programs are developed for potential use in cancer care markets in the United States and internationally.

Key Stats

• Today's Range: $1.96 to $2.15
• 50-Day Range: $2.08 to $2.66
• 52-Week Range: $1.96 to $6.52
• Volume: 55,487 shs
• Average Volume: 45,714 shs
• Market Capitalization: $19.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Moderate Buy

Cellectar Biosciences Stock Analysis - MarketRank™

Cellectar Biosciences scored higher than 36% of companies evaluated by MarketBeat, and ranked 713th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cellectar Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Cellectar Biosciences has a consensus price target of $11.00, representing about 428.8% upside from its current price of $2.08.

Amount of Analyst Coverage

Cellectar Biosciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cellectar Biosciences are expected to grow in the coming year, from ($2.39) to ($2.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cellectar Biosciences is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cellectar Biosciences is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cellectar Biosciences has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.08% of the float of Cellectar Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Cellectar Biosciences has a short interest ratio ("days to cover") of 4.57.

Change versus previous month

Short interest in Cellectar Biosciences has recently increased by 14.46%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cellectar Biosciences does not currently pay a dividend.

Dividend Growth

Cellectar Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Cellectar Biosciences this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for CLRB on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cellectar Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.58% of the stock of Cellectar Biosciences is held by insiders.

Percentage Held by Institutions

16.41% of the stock of Cellectar Biosciences is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/24/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CLRB
• CIK: 1279704
• Web: www.cellectar.com
• Phone: (608) 441-8120
• Fax: 608-441-8121
• Employees: 11
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Cellectar Biosciences: $11.00
• High Price Target: $11.00
• Low Price Target: $11.00
• Potential Upside/Downside: +428.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.79 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -185.35%
• Return on Assets: -115.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.66
• Quick Ratio: 6.66

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.89 per share
• Price / Book: 1.10

Miscellaneous

• Outstanding Shares: 9,450,000
• Free Float: 9,208,000
• Market Cap: $19.66 million
• Optionable: No Data
• Beta: 0.56